Akebia Asks Court to Bar Astra From Patent Suits on Anemia Drug

Akebia and Otsuka asked a federal court in Delaware to rule that Vafseo -- a treatment for anemia associated with chronic kidney disease -- doesn’t infringe 12 patents owned by FibroGen and exclusively licensed to AstraZeneca.

• Akebia and Otsuka, partners in Vafseo’s U.S. marketing and sales, are seeking the court’s declaration that the patents shouldn’t have been issued and that vadadustat, the active ingredient in Vafseo, doesn’t infringe any valid claims of the patents, according to complaint filed Monday in federal court in Wilmington, Delaware
• An application for approval of vadadustat was submitted by Akebia to the U.S. ...